AI
| Followers | 843 |
| Posts | 122806 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Friday, November 10, 2006 6:29:04 PM
>They are looking for a major pharmaceutical (not GTC) to partner with MM-093<
If true, this is good news. GTC was never expected to more than a supplier of bulk protein for MM-093.
If MM-093 works in RA, its non-TNF-a MoA and presumably low incidence of side effects ought to put it in a strong position to serve the large proportion of RA patients for whom a TNF-a drug does not do the trick. Moreover, MM-093 should be much safer than Rituxan.
Although it’s still early, it’s not unreasonable to think that MM-093 has bona fide blockbuster potential. If this is the case, even relatively thin supplier margins could eventually mean big money for a small company like GTC (#msg-8111599).
Having a Big Pharma promoting MM-093, if that comes to pass, would mean even more money for GTC. Regards, Dew
p.s. You earned your moderator’s salary and then some today
If true, this is good news. GTC was never expected to more than a supplier of bulk protein for MM-093.
If MM-093 works in RA, its non-TNF-a MoA and presumably low incidence of side effects ought to put it in a strong position to serve the large proportion of RA patients for whom a TNF-a drug does not do the trick. Moreover, MM-093 should be much safer than Rituxan.
Although it’s still early, it’s not unreasonable to think that MM-093 has bona fide blockbuster potential. If this is the case, even relatively thin supplier margins could eventually mean big money for a small company like GTC (#msg-8111599).
Having a Big Pharma promoting MM-093, if that comes to pass, would mean even more money for GTC. Regards, Dew
p.s. You earned your moderator’s salary and then some today
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
